News for Akebia Therapeutics, Inc. (AKBA)

Akebia Therapeutics' Vafseo expansion may boost future growth despite Auryxia's exclusivity loss. Read why AKBA stock is rated a hold.

Akebia Therapeutics (AKBA) has released findings from the vadadustat global phase 3 clinical program in the Journal of the American Society of Nephrology. The a

H.C. Wainwright's analyst, Matthew Caufield, has initiated coverage of Akebia Therapeutics (AKBA) with a Buy rating and set a price target of $8. Akebia's produ

Akebia Therapeutics (AKBA) has granted stock options for 137,000 shares to new employees. The exercise price for these options is set at $3.03 per share

**media[643748]**

Vadadustat clinical data on display for nephrologists and healthcare providers CAMBRIDGE, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc

**media[637939]**

**media[633082]**

Release Date: May 08, 2025For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Akebia Therapeuti

Refinitiv StreetEvents Event TranscriptE D I T E D V E R S I O NAKBA.OQ - Akebia Therapeutics IncQ1 2025 Akebia Therapeutics Inc Earnings CallMay 08, 2025 / 1

**media[617621]**

PR NewswireTOKYO, May 7, 2025 TOKYO, May 7, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today annou

**media[583513]**

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 100 points on Thursday. The Dow traded up 0.63% to 42,230.78 whil...

U.S. stock futures were lower this morning, with the Dow futures falling around 200 points on Thursday. Shares of JOYY Inc. YY fell sharply in today's pre-mark...

We all have heard the phrase ‘value isn’t always visible at first glance’ at least once in our lifetime and this isn’t something to overlook, particularly when you are playing the stock game.

U.S. stock futures were lower this morning, with the Dow futures falling around 0.1% on Tuesday. Shares of Hallador Energy Company HNRG fell sharply in today's...

Akebia Therapeutics is currently shifting focus from Auryxia to Vafseo due to Auryxia’s declining revenues. See why I reiterate my buy rating for AKBA stock.

PR NewswireCAMBRIDGE, Mass., Jan. 2, 2025 CAMBRIDGE, Mass., Jan. 2, 2025 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical co